Transplantation · 2009 · 118 citations · 22 references
PharmacyNephrologySurgeryKidney TransplantationRenal PharmacotherapyTransplant SurgeryAntimetabolite TherapyCalcineurin Inhibitor TherapyCalcineurin InhibitorsGraft SurvivalImmunosuppression In Kidney TransplantationImmunosuppressive TherapyAntimetabolite ImmunosuppressantsCalcineurin Inhibitor ImmunosuppressionImmunosuppressive Antimetabolite RegimensImmunosuppressive ConditioningLong-term Graft FunctionLong-term Graft SurvivalMycophenolic Acid TherapyTacrolimus Therapy
BACKGROUND: There have been striking changes during the last 10 years concerning the choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney transplantation. METHODS: A retrospective analysis of 51,303 patients undergoing deceased-donor kidney transplantation during 1998 to 2007 was performed using multivariate regression analysis. All patients received cyclosporine A (CsA) or tacrolimus (Tac) with azathioprine (AZA) or mycophenolic acid (MPA) on an intention-to-treat basis with corticosteroids plus/minus antibody induction. Graft survival rates and secondary outcomes were analyzed. A subanalysis was performed for transplants undertaken during 2002 to 2007, in which all patients were treated with MPA plus corticosteroids and CsA or Tac. RESULTS: All-cause graft failure and death-censored graft failure to 5 years posttransplant did not differ significantly between Tac and CsA. We found no evidence in support of previous claims that MPA results in superior long-term graft survival compared with AZA treatment. At the end of year 1, Tac was associated with a lower risk for serum creatinine more than or equal to 130 mumol/L (P<0.001) and hypercholesterolemia (P<0.001) versus CsA, but a higher risk for de novo posttransplant diabetes (P<0.001). MPA treatment was associated with a lower risk of acute rejection (P<0.001) but a higher risk of hospitalization because of infection (P<0.001) versus AZA. CONCLUSIONS: Five-year graft survival in deceased-donor kidney transplant recipients is equivalent in patients receiving CsA- or Tac-based immunosuppression, and in those receiving MPA or AZA. The absence of a survival benefit with modern agents is relevant in the current cost-conscious era of prescribing.
22
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Henrik Ekberg, Hélio Tedesco‐Silva, A. Demirbaş et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text
Diabetes Mellitus after Kidney Transplantation in the United States
Bertram L. Kasiske, Jon J. Snyder, David T. Gilbertson et al. · American Journal of Transplantation · 2003 · 1.3K citations · Full text
Medicine, Nephrology, Surgery +15